Methotrexate (MTX) has demonstrated significant activity against relapsed and metastatic osteosarcoma. However, there is little published data to indicate the appropriate dose for MTX when given as a component of a multidrug regimen for the treatment of osteosarcoma. Therefore, the investigators at
โฆ LIBER โฆ
Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study
โ Scribed by Bacci, Gaetano; Gherlinzoni, Franco; Picci, Piero; Van Horn, James R.; Jaffe, Norman; Guerra, Aristide; Ruggieri, Pietro; Biagini, Roberto; Capanna, Rodolfo; Toni, Aldo; Mercuri, Mario; Dallari, Dante; Campanacci, Mario
- Book ID
- 120248577
- Publisher
- Elsevier Science
- Year
- 1986
- Weight
- 843 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0277-5379
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A randomized study comparing high-dose m
โ
Krailo, M. ;Ertel, I. ;Makley, J. ;Fryer, C. J. H. ;Baum, E. ;Weetman, R. ;Yunis
๐
Article
๐
1987
๐
John Wiley and Sons
๐
English
โ 591 KB
Adjuvant six cycles of high-dose adriamy
โ
Dr. Takashi Fukutomi; Sadako Akashi; Takeshi Nanasawa; Hiroshi Yamamoto
๐
Article
๐
1995
๐
John Wiley and Sons
๐
English
โ 398 KB
A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients. The six-cycl